Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CPA1 | P15085 | 7/20 | 0.50 |
| ▸ | CPA3 | P15088 | 3/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740079 | 0.85 | MAPT (0.44) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL1155203 | 0.80 | TRPA1 (0.38) | CYP1A2 | |
| SCHEMBL4664822 | 0.78 | CYP1A2 (1.00) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL3741895 | 0.76 | EPHX1 (0.57) | — | |
| SCHEMBL3734387 | 0.76 | EPHX1 (0.57) | — | |
| SCHEMBL22115491 | 0.76 | CYP1A2 (0.95) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL9875948 | 0.76 | CYP1A2 (0.95) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL27291058 | 0.76 | CYP1A2 (0.95) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL1462830 | 0.74 | CYP1A2 (0.44) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL4329261 | 0.73 | CYP1A2 (0.36) | CYP1A2CPA1CPA3FOLH1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | CYP1A2 966/4885CPA1 2051/4885CPA3 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.